T-ALL

ALL diagnostics: challenges and considerations

Torsten Haferlach

Results of the COG AALL0434 trial for T-cell malignancies

Kimberly Dunsmore

The ALL frontier: should T-ALL be classed as a different disease?

Elizabeth Macintyre

Making an IMPACT in ALL therapy: how can cure rates be improved?

Nelarabine as first-line treatment for T-cell ALL: facing the problem up-front

Recent subtypes of ALL: Ph-like ALL and ETP ALL

Anjali Advani et al.

The future of inhibiting Bcl2 for the treatment of T-ALL

The serine biosynthesis pathway and its role in T-ALL

Understanding the RPL10 R98S mutation in T-ALL